Page 4 - Clinical Evolution News Today

Immunity-centric biotech firm lands $60m in Series A funding Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies. New York City- and Tel Aviv-based biotechnology firm Immunai has secured another $60m in Series A funding, bringing the company’s total funding landed to date to more than $80m. Immunai’s technology integrates multi-omic single-cell analytics and mac...

A peer-reviewed study indicates that the company’s antigen test could be more selective in detecting contagious COVID-19 patients than PCR testing.

The collaboration between the Jameel Clinic and pharma firm will harness artificial intelligence and machine learning in developing health solutions. The Abdul Latif Jameel Clinic for Machine Learning in Health at the Massachusetts Institute of Technology (MIT) is forging a long-term partnership with Sanofi. The research teams will work together to develop and apply artificial (AI) and machine learning (ML) technology to advance drug discovery, development of treatme...

The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.

Calyx spins off medical imaging, eClinical solutions firm Formerly Parexel Informatics, the renamed clinical research technology company has broken off and will operate as an independent company going forward. Calyx—a UK-based company offering medical imaging, eClinical and regulatory services to clinical research clients—has shed the name Parexel Informatics in favor of its new moniker. After this strategic separation, the company will continue its work pursuing...

Pfizer pours $25m into Vedantas Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II st...

Grifols to launch trial for potential COVID-19 therapy The subcutaneously administered immunoglobulin, if successful, would provide rapid immunity against the virus behind the deadly global pandemic. Biopharmaceutical firm Grifols, which specializes in development of therapies harnessing plasma-derived proteins, has announced it is kicking off a clinical trial in Spain to test the viability of a potential COVID-19 treatment. Based on the company’s immunoglobulin Ga...

The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment. Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments...

Florida doctor pleads guilty to clinical trial data fraud A Miami physician has owned up to falsifying research data and patient participation figures for a pediatric asthma trial conducted from 2013 to 2016. Yvelice Villaman Bencosme of Miami, Florida, has entered a guilty plea in US District Court for the Southern District of Florida, in response to one count of conspiracy to commit wire fraud. Bencosme (who served as primary investigator for clinical purportedly c...

Repurposing existing drugs accelerates discovery: XenoTech Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO. Pharmaceutical companies and their development partners are continually looking for safe, efficient ways to accelerate delivery of therapies to the patients that need them—especially in the face of the COVID-19 pandemic. One appealing path to new treatmen...